Baird lowered the firm’s price target on Praxis Precision (PRAX) to $73 from $117 and keeps an Outperform rating on the shares. The firm updated its model following its Q4 report where Ulixacaltamide is no longer essential for upside.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision Medicines: A Compelling Buy Amidst Promising Pipeline Developments
- Praxis Precision price target lowered to $105 from $120 at H.C. Wainwright
- Praxis Precision price target lowered to $65 from $111 at Deutsche Bank
- Positive Outlook on Praxis Precision Medicines Amidst Phase 3 ET Program Challenges
- Praxis Precision price target lowered to $61 from $114 at TD Cowen